|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Tea Tree Genome Provides Insights into Tea Flavor and Independent Evolution of Caffeine Biosynthesis显示文摘茶是世界有巨大的经济、药用、文化的重要性的最旧、很流行的包含咖啡因的饮料。这里,我们在场第一个高质量的核苷酸序列充满重复(80.9%) ,栽培的茶树山茶 sinensis 的 3.02-Gb 染色体。我们证明茶树的一种非常地大的染色体尺寸从一些 LTR retrotransposon 家庭的慢、稳定、长期的扩大被结果。除了一个最近的整个染色体的复制事件,基因的系特定的扩大把新陈代谢的生合成与 flavonoid 联系了被发现,它提高 catechin 生产,萜烯酶激活,和应力公差,为茶风味和改编的重要特征。我们相对可可子和咖啡表明一个独立人士和茶咖啡因合成小径的快速的进化。在 25 山茶种类之中的比较研究表明那更高的表情大多数 flavonoid- 和咖啡因铺平 -- 然而并非 theanine 相关的基因贡献 catechins 和咖啡因的增加的生产并且因此提高处理茶的适用性和茶质量。这些新奇调查结果为进一步的 metabolomic 和典型生合成小径的功能的 genomic 精炼铺平道路并且将帮助开发将最后满足并且吸引世界范围的更多的茶喝酒者的茶风味的一个更多样化的集合。 | En-Hua Xia Hai-Bin Zhang Jun Sheng Kui Li Qun-Jie Zhang Changhoon Kim Yun Zhang Yuan Liu Ting Zhu Wei Li Hui Huang Yan Tong Hong Nan Cong Shi Chao Shi Jian-Jun Jiang Shu-Yan Mao Jun-Ying Jiao Dan Zhang Yuan Zhao You-Jie Zhao Li-Ping Zhang Yun-Long Liu Ben-Ying Liu Yue Yu Sheng-Fu Shao De-Jiang Ni Evan E. Eichler Li-Zhi Gao | 2017 | Molecular Plant2017，10，6： | 113 |
| 2 | Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion显示文摘The recent outbreak of coronavirus disease(COVID-19)caused by SARS-CoV-2 infection in Wuhan,China has posed a serious threat to global public health.To develop specific anti-coronavirus therapeutics and prophylactics,the molecular mechanism that underlies viral infection must first be defined.Therefore,we herein established a SARS-CoV-2 spike(S)protein-mediated cell-cell fusion assay and found that SARS-CoV-2 showed a superior plasma membrane fusion capacity compared to that of SARS-CoV.We solved the X-ray crystal structure of six-helical bundle(6-HB)core of the HR1 and HR2 domains in the SARS-CoV-2 S protein S2 subunit revealing that several mutated amino acid residues in the HR1 domain may be associated with enhanced interactions with the HR2 domain.We previously developed a pan-coronavirus fusion inhibitor,EK1,which targeted the HR!domain and could inhibit infection by divergent human coronaviruses tested,including SARS-CoV and MERS-CoV.Here we generated a series of lipopeptides derived from EK1 and found that EK1C4 was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus infection with IC50s of 1.3 and 15.8 nM,about 241-and 149-fold more potent than the original EK1 peptide,respectively.EK1C4 was also highly effective against membrane fusion and infection of other human coronavirus pseudoviruses tested,including SARS-CoV and MERS-CoV,as well as SARSr-CoVs,and potently inhibited the replication of 5 live human coronaviruses examined,including SARS-CoV-2.Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from infection,suggesting that EK1C4 could be used for prevention and treatment of infection by the currently circulating SARS-CoV-2 and other emerging SARSr-CoVs. | Shuai Xia Meiqin Liu Chao Wang Wei Xu Qiaoshuai Lan Siliang Feng Feifei Qi Linlin Bao Lanying Du Shuwen Liu Chuan Qin Fei Sun Zhengli Shi Yun Zhu Shibo Jiang Lu Lu | 2020 | Cell Research2020，30，4： | 81 |
| 3 | Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein显示文摘Very recently,a novel coronavirus,2019-nCoV,emerged in Wuhan,China and then quickly spread worldwide,resulting in>17,388 confirmed cases and 361 deaths as of 3 February 2020,thus calling for the development of safe and effective therapeutics and prophylatics.1,2 Similar to severe acute respiratory syndrome(SARS)-CoV,2019-nCoV belongs to lineage B betacoronavirus,and it has the ability to utilize human angiotensin-converting enzyme 2(ACE2)as a receptor to infect human cells. | Shuai Xia Yun Zhu Meiqin Liu Qiaoshuai Lan Wei Xu Yanling Wu Tianlei Ying Shuwen Liu Zhengli Shi Shibo Jiang Lu Lu | 2020 | Cellular & Molecular Immunology2020，17，7： | 27 |
| 4 | Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma显示文摘AIM To evaluate the long-term effectiveness and late toxicities of paclitaxel(PTX) plus cisplatin(DDP) with concurrent radiotherapy for locally advanced esophageal squamous cancer.METHODS Between 2008 and 2011, 76 patients were enrolled in a phase Ⅱ study on the treatment of loco-regionally advanced esophageal cancer with radiotherapy(68.4 Gy/44 fractions or 61.2 Gy/34 fractions) combined with 4-cycle chemotherapy consisting of DDP(25 mg/m^2 per day for 3 d) and PTX(175 mg/m^2 for 3 h). The primary endpoints were overall survival and progression-free survival, and the secondary endpoints were toxicity and the treatment failure pattern.RESULTS A total of 76 patients were enrolled in this study, of whom 63.2% finished the whole regimen. The 5-year survival rates for the per-protocol population and intent-to-treat population were 25.4% and 26.4%, respectively, and the median survival rates were 23.7 mo and 28.5 mo, respectively. Grade 3 or 4 late toxicity was observed in only one patient(heart failure). In log-rank analysis, the pretreatment stage(stage Ⅱ + Ⅲ: 36.1 mo vs stage Ⅳ: 14.9 mo) and the completed cycle(1-3 cycles: 16.1 mo vs 4 cycles: 35.5 mo) were significant prognostic factors(P = 0.037 < 0.05 and P = 0.013 < 0.05).CONCLUSION Radiotherapy combined with chemotherapy consisting of PTX and DDP is a safe and effective definitive treatment for loco-regionally advanced esophageal squamous cancer. | Han-Ting Zhu Da-Shan Ai Hua-Rong Tang Harun Badakhshi Jian-Hong Fan Jia-Ying Deng Jun-Hua Zhang Yun Chen Zhen Zhang Yi Xia Xiao-Mao Guo Guo-Liang Jiang Kuai-Le Zhao | 2017 | World Journal of Gastroenterology2017，23，3： | 14 |
| 5 | Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1:interim analysis of the randomized,controlled,phase 3,non-inferiority TALENT study显示文摘Background:Albuvirtide is a once-weekly injectable human immunodeficiency virus(HIV)-1 fusion inhibitor.We present interim data for a phase 3 trial assessing the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1-infected adults already treated with antiretroviral drugs.Methods:We carried out a 48-week,randomized,controlled,open-label non-inferiority trial at 12 sites in China.Adults on the World Health Organization(WHO)-recommended first-line treatment for>6 months with a plasma viral load>1000 copies/mL were enrolled and randomly assigned(1:1)to receive albuvirtide(once weekly)plus ritonavir-boosted lopinavir(ABT group)or the WHO-recommended second-line treatment(NRTI group).The primary endpoint was the proportion of patients with a plasma viral load below 50 copies/mL at 48 weeks.Non-inferiority was prespecified with a margin of 12%.Results:At the time of analysis,week 24 data were available for 83 and 92 patients,and week 48 data were available for 46 and 50 patients in the albuvirtide and NRTI groups,respectively.At 48 weeks,80.4%of patients in the ABT group and 66.0%of those in the NRTI group had HIV-1 RNA levels below 50 copies/mL,meeting the criteria for non-inferiority.For the per-protocol population,the superiority of albuvirtide over NRTI was demonstrated.The frequency of grade 3 to 4 adverse events was similar in the two groups;the most common adverse events were diarrhea,upper respiratory tract infections,and grade 3 to 4 increases in triglyceride concentration.Renal function was significantly more impaired at 12 weeks in the patients of the NRTI group who received tenofovir disoproxil fumarate than in those of the ABT group.Conclusions:The TALENT study is the first phase 3 trial of an injectable long-acting HIV drug.This interim analysis indicates that once-weekly albuvirtide in combination with ritonavir-boosted lopinavir is well tolerated and non-inferior to the WHO-recommended second-line regimen in patients with first-line treatment failure.Trial registration:ClinicalTrials.gov Identifier:NCT02369965;https://www.clinicaltrials.gov.Chinese Clinical Trial Registry No.ChiCTR-TRC-14004276;http://www.chictr.org.cn/enindex.aspx. | Bin Su Cheng Yao Qing-Xia Zhao Wei-Ping Cai Min Wang Hong-Zhou Lu Yuan-Yuan Chen Li Liu Hui Wang Yun He Yu-Huang Zheng Ling-Hua Li Jin-Feng Chen Jian-Hua Yu Biao Zhu Min Zhao Yong-Tao Sun Wen-Hui Lun Wei Xia Li-Jun Sun Li-Li Dai Tai-Yi Jiang Mei-Xia Wang Qing-Shan Zheng Hai-Yan Peng Yao Wang Rong-Jian Lu Jian-Hua Hu Hui Xing Yi-Ming Shao Dong Xie Tong Zhang Fu-Jie Zhang Hao Wu TALENT Study Team | 2020 | Chinese Medical Journal2020，，24： | 10 |
| 6 | The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin显示文摘Dear Editor,The rapid spread of SARS-CoV-2(also known as 2019-nCoV and HCoV-191),a novel lineage B betacoronavirus(βCoV),has caused a global pandemic of coronavirus disease(COVID-19).It has been speculated that RRAR,a unique furin-like cleavage site(FCS)in the spike protein(S),which is absent in other lineage BβCoVs,such as SARS-CoV,is responsible for its high infectivity and transmissibility. | Shuai Xia Qiaoshuai Lan Shan Su Xinling Wang Wei Xu Zezhong Liu Yun Zhu Qian Wang Lu Lu Shibo Jiang | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 8 |
| 7 | Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China显示文摘Objective Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.Methods A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients’ medical records. Multivariable logistic regression models were used to estimate the odds ratio(OR) and 95% confidence interval(95% CI) of the associations between comorbidities(cardiometabolic or non-cardiometabolic diseases), clinical severity, and treatment outcomes of COVID-19.Results Overall, 158(13.6%) patients were diagnosed with severe illness and 32(2.7%) had unfavorable outcomes. Hypertension(2.87, 1.30–6.32), type 2 diabetes(T2 DM)(3.57, 2.32–5.49),cardiovascular disease(CVD)(3.78, 1.81–7.89), fatty liver disease(7.53, 1.96–28.96), hyperlipidemia(2.15, 1.26–3.67), other lung diseases(6.00, 3.01–11.96), and electrolyte imbalance(10.40, 3.00–26.10)were independently linked to increased odds of being severely ill. T2 DM(6.07, 2.89–12.75), CVD(8.47,6.03–11.89), and electrolyte imbalance(19.44, 11.47–32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission(5.46,3.25–9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes(6.58, 1.46–29.64) within two weeks.Conclusion Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes. | MA Yan ZHU Dong Shan CHEN Ren Bo SHI Nan Nan LIU Si Hong FAN Yi Pin WU Gui Hui YANG Pu Ye BAI Jiang Feng CHEN Hong CHEN Li Ying FENG Qiao GUO Tuan Mao HOU Yong HU Gui Fen HU Xiao Mei HU Yun Hong HUANG Jin HUANG Qiu Hua HUANG Shao Zhen JI Liang JIN Hai Hao LEI Xiao LI Chun Yan LI Min Qing LI Qun Tang LI Xian Yong LIU Hong De LIU Jin Ping LIU Zhang MA Yu Ting MAO Ya MO Liu Fen NA Hui WANG Jing Wei SONG Fang Li SUN Sheng WANG Dong Ting WANG Ming Xuan WANG Xiao Yan WANG Yin Zhen WANG Yu Dong WU Wei WU Lan Ping XIAO Yan Hua XIE Hai Jun XU Hong Ming XU Shou Fang XUE Rui Xia YANG Chun YANG Kai Jun YUAN Sheng Li ZHANG Gong Qi ZHANG Jin Bo ZHANG Lin Song ZHAO Shu Sen ZHAO Wan Ying ZHENG Kai ZHOU Ying Chun ZHU Jun Teng ZHU Tian Qing ZHANG Hua Min WANG Yan Ping WANG Yong Yan 无 | 2020 | Biomedical and Environmental Sciences2020，33，12： | 8 |
| 8 | Metabolic Disorders Increase the Risk to Incident Cardiovascular Disease in Middle-aged and Elderly Chinese显示文摘Objective The association of metabolic syndrome (MetS) with cardiovascular diseases (CVD) has not been adequately explored in middle-aged and elderly Chinese.This study aimed to investigate MetS' prevalence and its impact on the CVD incidence in this specific population group.Methods A data set of a community-based prospective cohort study was analyzed.A total of 2300 subjects aged 40-94 years were followed up for the CVD events.MetS defined according to the JCDCG criteria was assessed at baseline,and the middle-aged and elderly groups were classified by the WHO definition.Results As compared with the middle-aged group,the prevalence of MetS increased by 0.6 times (34.6% vs.21.3%) and the incidence density of CVD increased by 4.9 times in the elderly group (52.3/1000 person-year vs.8.9/1000 person-year).Furthermore,the multivariate Cox regression revealed that the risk to CVD incidence was independently related to increased waist circumference in the middle-aged group (HR=2.23,P<0.01) and to elevated blood glucose in the elderly group (HR=1.39,P<0.01).Conclusion MetS was highly prevalent in middle-aged and elderly Chinese.MetS significantly increased the risk to CVD incidence in the elderly.All individuals with metabolic disorders should receive active clinical care to reduce the incidence of CVD. | ZHANG Ming Liang HOU Xu Hong ZHU Yun Xia LU Jun Xi PENG Liang Pu GU Hui Lin JIA Wei Ping | 2012 | Biomedical and Environmental Sciences2012，25，1： | 7 |
| 9 | Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer显示文摘Neoantigens are considered to be ultimate target of tumor immunotherapy due to their high tumor specificity and immunogenicity.Dendritic cell(DCs)vaccines based on neoantigens have exciting effects in treatment of some malignant tumors and are a promising therapeutic modality.Lung cancer is a lethal disease with the highest morbidity and mortality rate in the world.Despite the rapid development of targeted therapy and immune checkpoint inhibitors for lung cancer in recent years,their efficacy is still unsatisfactory overall.Therefore,there is an urgent unmet clinical need for lung cancer treatment.Here,we attempted to treat lung cancer using a personalized neoantigen peptide-pulsed autologous DC vaccine and conducted a single-arm,2 medical centers,pilot study initiated by the investigator(ChiCTR-ONC 16009100,NCT02956551).The patients enrolled were patients with heavily treated metastatic lung cancer.Candidate neoantigens were derived from whole-exome sequencing and RNA sequencing of fresh biopsy tissues as well as bioinformatics analysis.A total of 12 patients were enrolled in this study.A total of 85 vaccine treatments were administered with a median value of 5 doses/person(range:3-14 doses/person).In total,12-30 peptide-based neoantigens were selected for each patient.AIl treatment-related adverse events were grade 1-2 and there were no delays in dosing due to toxic effects.The objective effectiveness rate was 25%;the disease control rate was 75%;the median progression-free survival was 5.5 months and the median overall survival was 7.9 months.This study provides new evidence for neoantigen vaccine therapy and new therapeutic opportunities for lung cancer treatment. | Zhenyu Ding Qing Li Rui Zhang Li Xie Yang shu Song Gao Peipei Wang Xiaoqing Su Yun Qin Yuelan Wang Juemin Fang Zhongzheng Zhu Xuyang Xia Guochao Wei Hui Wang Hong Qian Xianling Guo Zhibo Gao Yu Wang Yuquan Wei Qing Xu Heng Xu Li Yang | 2021 | Signal Transduction and Targeted Therapy2021，6，2： | 3 |
| 10 | Origin,virological features,immune evasion and intervention of SARS-CoV-2 Omicron sublineages显示文摘Recently,a large number of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variants continuously emerged and posed a major threat to global public health.Among them,particularly,Omicron variant(B.1.1.529),first identified in November 2021,carried numerous mutations in its spike protein(S),and then quickly spread around the world.Currently,Omicron variant has expanded into more than one hundred sublineages,such as BA.1,BA.2,BA.2.12.1,BA.4 and BA.5,which have already become the globally dominant variants.Different from other variants of concern(VOCs)of SARS-CoV-2,the Omicron variant and its sublineages exhibit increased transmissibility and immune escape from neutralizing antibodies generated through previous infection or vaccination,and have caused numerous re-infections and breakthrough infections.In this prospective,we have focused on the origin,virological features,immune evasion and intervention of Omicron sublineages,which will benefit the development of nextgeneration vaccines and therapeutics,including pan-sarbecovirus and universal anti-CoV therapeutics,to combat currently circulating and future emerging Omicron sublineages as well as other SARS-CoV-2 variants. | Shuai Xia Lijue Wang Yun Zhu Lu Lu Shibo Jiang | 2022 | Signal Transduction and Targeted Therapy2022，7，8： | 3 |
| 11 | Pan-coronavirus fusion inhibitors as the hope for today and tomorrow显示文摘The last two decades of the 21st century have seen emerging zoonotic coronavirus(CoV)diseases,including severe acute respiratory syndrome(SARS)(Holmes 2003),Middle East respiratory syndrome(MERS)(Graham et al.,2013)and coronavirus disease 2019(COVID-19)(Jiang et al.,2020). | Xinling Wang Shuai Xia Yun Zhu Lu Lu Shibo Jiang | 2021 | Protein & Cell2021，12，2： | 3 |
| 12 | Rapid and Sensitive Chemiluminescent Enzyme Immunoassay for the Determination of Neomycin Residues in Milk显示文摘Immunoassays greatly contribute to veterinary drug residue analysis.However,there are few reports on detecting neomycin residues by immunoassay.Here,a rapid and sensitive chemiluminescent enzyme immunoassay(CLIEA)was successfully developed for neomycin | LUO Peng Jie ZHANG Jian Bo WANG Hua Li CHEN Xia WU Nan ZHAO Yun Feng WANG Xiao Mei ZHANG Hong ZHANG Ji Yue ZHU Lei JIANG Wen Xiao | 2016 | Biomedical and Environmental Sciences2016，29，5： | 3 |
| 13 | Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial显示文摘Tocilizumab has been reported to attenuate the“cytokine storm”in COVID-19 patients.We attempted to verify the effectiveness and safety of tocilizumab therapy in COVID-19 and identify patients most likely to benefit from this treatment.We conducted a randomized,controlled,open-label multicenter trial among COVID-19 patients.The patients were randomly assigned in a 1:1 ratio to receive either tocilizumab in addition to standard care or standard care alone.The cure rate,changes of oxygen saturation and interference,and inflammation biomarkers were observed.Thirty-three patients were randomized to the tocilizumab group,and 32 patients to the control group.The cure rate in the tocilizumab group was higher than that in the control group,but the difference was not statistically significant(94.12%vs.87.10%,rate difference 95%CI−7.19%–21.23%,P=0.4133).The improvement in hypoxia for the tocilizumab group was higher from day 4 onward and statistically significant from day 12(P=0.0359).In moderate disease patients with bilateral pulmonary lesions,the hypoxia ameliorated earlier after tocilizumab treatment,and less patients(1/12,8.33%)needed an increase of inhaled oxygen concentration compared with the controls(4/6,66.67%;rate difference 95%CI−99.17%to−17.50%,P=0.0217).No severe adverse events occurred.More mild temporary adverse events were recorded in tocilizumab recipients(20/34,58.82%)than the controls(4/31,12.90%).Tocilizumab can improve hypoxia without unacceptable side effect profile and significant influences on the time virus load becomes negative.For patients with bilateral pulmonary lesions and elevated IL-6 levels,tocilizumab could be recommended to improve outcome. | Dongsheng Wang Binqing Fu Zhen Peng Dongliang Yang Mingfeng Han Min Li Yun Yang Tianjun Yang Liangye Sun Wei Li Wei Shi Xin Yao Yan Ma Fei Xu Xiaojing Wang Jun Chen Daqing Xia Yubei Sun Lin Dong Jumei Wang Xiaoyu Zhu Min Zhang Yonggang Zhou Aijun Pan Xiaowen Hu Xiaodong Mei Haiming Wei Xiaoling Xu | 2021 | Frontiers of Medicine2021，15，3： | 2 |
| 14 | Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection:a randomized trial显示文摘It's a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in thedfferentiated populations with complex diseases,as stable coronary heart disease.Here,in an adaptive,31-center,randomized,double-blind trial invoving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI),a kind of polyphamacological drug with high quality control,or placebo(0.9%saline),with 76-day following-up,we firstly confrmed that DHl couldincrease the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire(ASAQ-AF220)(12.78%at Day 30,95%confidence interval[C]5.86-19.71%,P=0.0003,13.82%at Day 6C0,95%CI 6.82-20.82%,P=0.0001and 8.95%at Day 90,95%CI 2.06-15.85%,P=0.01).We also found that there were no significant differences in new-onset major vascularevents(P=0.8502)and serious adverse events(P=0.9105)between DHl and placebo.After performing the RNA sequencing in 62 selectedpatients,we developed a systemic modular approach tp identfy differentilly expressed modules(DEMs)of DHI with the Z_(summay)valueless than 0 compared with the control group,calculated by weighted gene co-expression network analysis(WGCNA),and sketched out thebasic framework on a modular map with 25 functional modules targeted by DII.Furthermore,the effective therapeutic module(ETM),defined as the highest corelation value with the phenotype alteration(SAQ-AF,the change in SAQ-AF at Day 30 from baseline)calculatedby WGCNA,was identifed in the population with the best effect(ASAQ-AF240),which is related to anticoagulation and regulation ofcholesterol metabolism.We assessed the modular flexbility of this ETM using the global topological D value based on Euclidean distance,which is corelated with phenotype alteration(r^(2):0.8204,P=0.019)by linear regression.Our study identified the ant-angina therapeuticmodule in the effective population treated by the multi-target drug.Modular methods facilitate the discovery of network pharmacologicalmechanisms and the advancement of precision medicine.(ClinicalTrials.gov identifier:NCTO1681316). | Jun Liu Dan-Dan Li Wei Dong Yu-Qi Liu Yang Wu Da-Xuan Tang Fu-Chun Zhang Meng Qiu Qi Hua Jing-Yu He Jun Li Bai Du Ting-Hai Du Lin-Lin Niu Xue-Jun Jiang Bo Cui Jiang-Bin Chen Yang-Gan Wang Hai-Rong Wang Qin Yu Jing He Yi-Lin Mao Xiao-Fang Bin Yue Deng Yu-Dan Tian Qing-Hua Han Da-Jin Liu Li-Qin Duan Ming-Jun Zhao Cui-Ying Zhang Hai-Ying Dai Ze-Hua Li Ying Xiao You-Zhi Hu Xiao-Yu Huang Kun Xing Xin Jiang Chao-Feng Liu Jing An Feng-Chun Li Tao Tao Jin-Fa Jiang Ying Yang Yao-Rong Dong Lei Zhang Guang Fu Ying Li Shu-Wei Huang Li-Ping Dou Lan-Jun Sun Ying-Qiang Zhao Jie Li Yun Xia Jun Liu Fan Liu Wen-Jin He Ying Li Jian-Cong Tan Yang Lin Ya-Bin Zhou Jian-Fei Yang Guo-Qing Ma Hui-Jun Chen He-Ping Liu Zong-Wu Liu Jian-Xiong Liu Xiao-Jia Luo Xiao-Hong Bin Ya-Nan Yu Hai-Xia Dang Bing Li Fei Teng Wang-Min Qiao Xiao-Long Zhu Bing-Wei Chen Qi-Guang Chen Chun-Ti Shen Yong-Yan Wang Yun-Dai Chen Zhong Wang | 2021 | Signal Transduction and Targeted Therapy2021，6，10： | 2 |
| 15 | Formation mechanism of multi-functional black silicon based on optimized deep reactive ion etching technique with SF_6/C_4F_8显示文摘This paper reports a controllable multi-functional black silicon surface with nanocone-forest structures fabricated by an optimized deep reactive ion etching(DRIE)technique using SF6/C4F8 in cyclic etching-passivation process,which is maskless,effective and controllable.The process conditions are investigated by systematically comparative experiments and core parameters have been figured out,including etching process parameters,pre-treatment,patterned silicon etching and inclined surface etching.Based on the experimental data,the formation mechanism of nanocone shape is developed,which provides a novel view for in-depth understanding of abnormal phenomena observed in the experiments under different process situations.After the optimization of the process parameters,the black silicon surfaces exhibit superhydrophobicity with tunable reflectance.Additionally,the quantitative relationship between nanocones aspect ratio and surface reflectance and static contact angle is obtained,which demonstrates that black silicon surfaces with unique functional properties(i.e.,cross-combination of reflectance and wettability)can be achieved by controlling the morphology of nanostructures. | ZHU Fu Yun ZHANG Xiao Sheng ZHANG Hai Xia | 2015 | Science China(Technological Sciences)2015，58，2： | 2 |
| 16 | Imbalance of interleukin‐17‐producing CD 4 T cells/regulatory T cells axis occurs in remission stage of patients with hepatitis B virus‐related acute‐on‐chronic liver failure显示文摘 | Geng‐Lin Zhang Dong‐Ying Xie Bing‐Liang Lin Chan Xie Yi‐Nong Ye Liang Peng Shao‐Quan Zhang Yu‐Feng Zhang Qing Lai Jian‐Yun Zhu Ying Zhang Yang‐Su Huang Zhao‐Xia Hu Zhi‐Liang Gao | 2013 | J Gastroenterol Hepatol2013，，3： | 2 |
| 17 | Improvement of microalgae lipid productivity and quality in an ion-exchange-membrane photobioreactor using real municipal wastewater显示文摘To improve the productivity and quality of microalgae-based biodiesel when using municipal wastewater(MW)as nutrients source,an ion-exchange-membrane photobioreactor(IEM-PBR)was used in this study to eliminate the negative effects of pollutants in MW on microalgae Chlorella vulgaris and Scenedesmus obliquus.In the IEM-PBR,the real MW and microalgae cultures were separated in two chambers by the ion-exchange-membranes(IEMs).Nutrients(N,P,etc.)in the MW permeated into microalgae cultures through the IEMs,while pollutants(suspended solids,competitors,etc.)in the MW could hardly permeate into microalgae cultures.As a result,the lipid productivity in the IEM-PBR was improved to 85.7 mg/(L·d)for C.vulgaris and 111.8 mg/(L·d)for S.obliquus,which was slightly higher than that in the traditional photobioreactor(T-PBR)with real MW after centrifugation(82.5 mg/(L·d)for C.vulgaris and 105.8 mg/(L·d)for S.obliquus),but much higher than that in the T-PBR with untreated MW and primary MW(with lipid productivity of 20-30 mg/(L·d)).Besides,the lipid quality obtained in the IEM-PBR had higher proportion of cetane number(ca.60%)and lower linolenic acid content(ca.8%),which showed a superior quality in the IEM-PBR to that in the T-PBR.It demonstrated that the IEM-PBR is an effective approach to improve the productivity and quality of microalgae biodiesel. | Chang Haixing Fu Qian Huang Yun Xia Ao Liao Qiang Zhu Xun | 2017 | International Journal of Agricultural and Biological Engineering2017，10，1： | 2 |
| 18 | Inverted U-Shaped Associations between Glycemic Indices and Serum Uric Acid Levels in the General Chinese Population:Findings from the China Cardiometabolic Disease and Cancer Cohort(4C)Study显示文摘Objective The relationship between serum uric acid(SUA)levels and glycemic indices,including plasma glucose(FPG),2-hour postload glucose(2 h-PG),and glycated hemoglobin(HbA1 c),remains inconclusive.We aimed to explore the associations between glycemic indices and SUA levels in the general Chinese population.Methods The current study was a cross-sectional analysis using the first follow-up survey data from The China Cardiometabolic Disease and Cancer Cohort Study.A total of 105,922 community-dwelling adults aged≥40 years underwent the oral glucose tolerance test and uric acid assessment.The nonlinear relationships between glycemic indices and SUA levels were explored using generalized additive models.Results A total of 30,941 men and 62,361 women were eligible for the current analysis.Generalized additive models verified the inverted U-shaped association between glycemic indices and SUA levels,but with different inflection points in men and women.The thresholds for FPG,2 h-PG,and HbA1 c for men and women were 6.5/8.0 mmol/L,11.0/14.0 mmol/L,and 6.1/6.5,respectively(SUA levels increased with increasing glycemic indices before the inflection points and then eventually decreased with further increases in the glycemic indices).Conclusion An inverted U-shaped association was observed between major glycemic indices and uric acid levels in both sexes,while the inflection points were reached earlier in men than in women. | ZHU Yuan Yue ZHENG Rui Zhi WANG Gui Xia CHEN Li SHI Li Xin SU Qing XU Min XU Yu CHEN Yu Hong YU Xue Feng YAN Li WANG Tian Ge ZHAO Zhi Yun QIN Gui Jun WAN Qin CHEN Gang GAO Zheng Nan SHEN Fei Xia LUO Zuo Jie QIN Ying Fen HUO Ya Nan LI Qiang YE Zhen ZHANG Yin Fei LIU Chao WANG You Min WU Sheng Li YANG Tao DENG Hua Cong ZHAO Jia Jun CHEN Lu Lu MU Yi Ming TANG Xu Lei HU Ru Ying WANG Wei Qing NING Guang LI Mian LU Jie Li BI Yu Fang | 2021 | Biomedical and Environmental Sciences2021，34，1： | 2 |
| 19 | Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation显示文摘The COVID-19 pandemic poses a global threat to public health and economy.The continuously emerging SARS-CoV-2 variants present a major challenge to the development of antiviral agents and vaccines.In this study,we identified that EK1 and cholesterol-coupled derivative of EK1,EK1C4,as pan-CoV fusion inhibitors,exhibit potent antiviral activity against SARS-CoV-2 infection in both lung-and intestine-derived cell lines(Calu-3 and Caco2,respectively).They are also effective against infection of pseudotyped SARS-CoV-2 variants B.1.1.7(Alpha)and B.l.1.248(Gamma)as well as those with mutations in S protein,including N417T,E484K,N501Y,and D614G,which are common in South African and Brazilian variants.Crystal structure revealed that EK1 targets the HR1 domain in the SARS-CoV-2 S protein to block virus-cell fusion and provide mechanistic insights into its broad and effective antiviral activity.Nasal administration of EK1 peptides to hACE2 transgenic mice significantly reduced viral titers in lung and intestinal tissues.EK1 showed good safety profiles in various animal models,supporting further clinical development of EK1-based pan-CoV fusion inhibitors against SARS-CoV-2 and its variants. | Shuai Xia Qiaoshuai Lan Yun Zhu Chao Wang Wei Xu Yutang Li Lijue Wang Fanke Jiao Jie Zhou Chen Hua Qian Wang Xia Cai Yang Wu Jie Gao Huan Liu Ge Sun Jan Munch Frank Kirchhoff Zhenghong Yuan Youhua Xie Fei Sun Shibo Jiang Lu Lu | 2021 | Signal Transduction and Targeted Therapy2021，6，8： | 2 |
| 20 | Medium-low temperature hydrothermal hydrolysis kinetic characteristics of concentrated wet microalgae biomass显示文摘To improve microalgae biomass utilization efficiency during biofuel production process,medium-low temperature hydrothermal hydrolysis pretreatment was adopted in this study.The pretreatment kinetic characteristics of concentrated wet microalgae Chlorella vulgaris biomass(50 g/L)under medium-low temperature hydrolysis(100°C-200°C)were experimentally investigated.The hydrothermal hydrolysis kinetics describing the coupled effects of temperature,initial pressure and retention time then were proposed using response surface methodology(RSM).The maximum carbohydrate yield reached 327.3 mg/g dried biomass under initial pressure of 4 MPa at reaction temperature of 150°C for 120 min.The maximum protein yield(321.5 mg/g dried biomass)was obtained under initial pressure of 4 MPa at reaction temperature of 200°C for 60 min.Based on the hydrothermal hydrolysis kinetic models,it was confirmed that temperature was the most important factor affecting both carbohydrate and protein release during hydrothermal hydrolysis process.Hydrothermal initial pressure and retention time were significant to carbohydrate release,but not to protein release.While,lipid was mainly distributed in microalgae residual and almost did not exist in supernatant(about 8.03 mg/g).And with assistance of mixed hexane and methanol(the ratio of hexane to methanol was 7:3),67.69%of microalgae lipid was extracted out from hydrothermal hydrolysed microalgae residual(123.3 mg/g dried biomass). | Ding Xiaojian Huang Yun Liao Qiang Fu Qian Xia Ao Xiao Chao Zhu Xun Reungsang Alissara Liu Zhidan | 2017 | International Journal of Agricultural and Biological Engineering2017，10，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员